|
汪超教授课题组在Adv. Mater.上发表论文
|
发布时间:2021-11-22 点击:12
|
题目: | Mesenchymal Stem Cell-Derived Extracellular Vesicles with High PD-L1 Expression for Autoimmune Diseases Treatment
| 作者: | Fang Xu,1 Ziying Fei,1 Huaxing Dai,1 Jialu Xu,1 Qin Fan,1 Shufang Shen,1 Yue Zhang,1 Qingle Ma,1 Jiacheng Chu,1 Fei Peng,2 Fangfang Zhou,3 Zhuang Liu,1 and Chao Wang1,*
| 单位: | 1Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China 2Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02114, USA 3Institutes of Biology and Medical Science, Soochow University, Suzhou 215123, China
| 摘要: | Autoimmune diseases are the third most common disease influencing the quality of life of many patients. Here, a programmed cell death-ligand 1+(PD-L1) mesenchymal stem cell (MSC) derived extracellular vesicles (MSC-sEVs-PD-L1) using lentivirus-mediated gene transfection technology is developed for reconfiguration of the local immune microenvironment of affected tissue in autoimmune diseases. MSC-sEVs-PD-L1 exhibits an impressive ability to regulate various activated immune cells to an immunosuppressed state in vitro. More importantly, in dextran sulfate sodium-induced ulcerative colitis (UC) and imiquimod-induced psoriasis mouse models, a significantly high accumulation of MSC-sEVs-PD-L1 is observed in the inflamed tissues compared to the PD-L1+ MSCs. Therapeutic efficiency in both UC and psoriasis mouse disease models is demonstrated using MSC-sEVs-PD-L1 to reshape the inflammatory ecosystem in the local immune context. A technology is developed using MSC-sEVs-PD-L1 as a natural delivery platform for autoimmune diseases treatment with high clinical potential.
| 影响因子: | 27.398
| 分区情况: | 一区
| 链接: | https://doi.org/10.1002/adma.202106265 |
责任编辑:向丹婷
|
|